News

The IND covers the company’s clinical development plan for a patented formulation of itraconazole (SUBA-Itraconazole) with improved bioavailability to study the treatment of basal cell carcinoma (BCC) in

As part of the partnership, both the firms will jointly evaluate both clinical and pre-clinical stage projects that will be identified and presented by BioLineRx through a Joint

As part of this collaboration, Ossianix’s new single Blood Brain Barrier (BBB) targeting domain antibody platform that is based on the shark VNAR structure will be used for

The trial is designed to evaluate the safety, tolerability and efficacy of PF-06252616 in boys aged six to less than ten years old diagnosed with DMD regardless of

Pursuant to the agreement Adapt has received from Lightlake a global license to develop and commercialize Lightlake’s intranasal naloxone opioid overdose reversal treatment. In exchange for licensing its

Its lead compound PPL-003 showed success in two studies in rabbits. In the first study, topical eye administration of PPL-003 at the highest feasible dose was well tolerated

PPD and ERT will work closely throughout all areas of the clinical development process to offer clients efficiencies through alignment of crucial aspects of service delivery, including budget

The Company believes this is an important breakthrough discovery for two reasons. The first is that it confirms that TRXE-009 is an important new potential treatment for melanoma,

As part of the deal, the two parties will jointly carry out the clinical proof of concept (PoC) trial of E6201, a dual-targeted FLT3 and MEK inhibitor for